QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in ...
This new panel marks the fourth FDA clearance of a QIAstat-Dx panel in 2024, and comes after the recent FDA clearances for other tests: QIAstat-Dx Gastrointestinal Panel 2 QIAstat-Dx Respiratory ...
It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback